The fact that no significant association was found in the current study between CYP metabolizer status, switching/discontinuing AD treatment and side effects in the hypothesised direction, aligns with the recommendation that genotyping is not indicated in psychiatry as a standard procedure prior treatment. Here, PPIG is linked to Alzheimer disease.